NCT00151125View on ClinicalTrials.gov

Phase II Study of IL-11 (Neumega) in Von Willebrand Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Von Willebrand Disease
Interventions
DRUG

recombinant interleukin-11

25 mcg/kg subcutaneously daily for seven days

DRUG

recombinant interleukin-11

50 mcg/kg subcutaneously daily for 7 days

DRUG

recombinant interleukin-11

10 mcg/kg subcutaneously daily for 7 days

Trial Locations (1)

15213-4306

Hemophilia Center of Western Pennsylvania and General Clinical Research Center, Pittsburgh

All Listed Sponsors
collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

collaborator

University of North Carolina

OTHER

lead

University of Pittsburgh

OTHER

NCT00151125 - Phase II Study of IL-11 (Neumega) in Von Willebrand Disease | Biotech Hunter | Biotech Hunter